Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune
system in different ways and stop cancer cells from growing. Giving vorinostat together with
lenalidomide may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when
given together with lenalidomide in treating patients with relapsed or refractory Hodgkin
lymphoma or non-Hodgkin lymphoma.